Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 216

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 216
---
PTs include Illumina, through its subsidiary Verinata,
Laboratory Corporation of America Holdings (Labcorp), Myriad Genetics, Inc. (Myriad), Natera, Inc. (Natera), and Quest Diagnostics Incorporated (Quest). We also compete with companies providing carrier screening tests such as Fulgent Genetics,
Labcorp, Myriad, Natera, and Quest. Each of these companies offers comprehensive carrier screening panels.

In the oncology market, our main competitors for our
therapy selection and response monitoring tests include Caris Life Sciences, Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Guardant Health, Inc., Neogenomics, and Tempus AI, Inc. As we expand our oncology offerings into
applications such as MRD testing, as well as potentially testing for early detection in the future, we anticipate facing competition from a broader universe of companies, including Exact Sciences, Grail, Haystack, which was acquired by Quest, and
Natera.

Many of our competitors, either alone or with their collaborators, may have greater financial and/or other resources than we do, including larger and more
established manufacturing capabilities and marketing, sales, and support functions. Other competitors are in the process of developing novel technologies which may lead to products that rival or replace our products. While we cannot assure you how
the market will evolve, we believe our four pillars of differentiation provide competitive advantages that are difficult for others to replicate.

For further
discussion of the risks we face relating to competition, see the section titled “Risk factors—Risks Related to Our Business and Strategy—If we cannot compete successfully with our competitors, we may be unable to increase or sustain
our revenue or to achieve and then sustain profitability.”

Intellectual Property

The long-term
success of our business depends on securing protection of our intellectual property through patent, trade secret, trademark, and other intellectual property rights. We also utilize non-disclosure agreements
and proprietary information and inventions assignment agreements with employees, consultants, contractors and other third parties and maintain physical security of our premises and physical and electronic security of our information technology
systems in order to strengthen the protection of our intellectual property.

As of June 30, 2025, we held nine U.S. issued patents, which expire between
August 2038 and March 2043, and 45 foreign patents, which expire between August 2038 and September 2041. Additionally, we had 14 pending U.S. patent applications and